Literature DB >> 3546119

Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.

G K Owens.   

Abstract

The hypothesis that a primary stimulus for aortic medial hypertrophy in spontaneously hypertensive rats (SHR) is increased blood pressure was tested by determining whether development of smooth muscle cell hypertrophy and hyperploidy in SHR could be dissociated from blood pressure levels in rats treated with various antihypertensive drugs with different mechanisms of action. Wistar-Kyoto rats (WKY) and SHR were treated between 2 and 5 months of age with captopril (375 mg/L), hydralazine (40 mg/L), or propranolol (1.5 mg/L) administered in their drinking water. Smooth muscle hypertrophy and hyperploidy were analyzed by morphometric evaluation of medial smooth muscle content, flow cytometric analysis of the frequency of polyploid smooth muscle cells, and biochemical estimates of smooth muscle cell number. All drugs significantly lowered blood pressure in SHR compared with untreated controls (order of efficacy: captopril greater than hydralazine greater than propranolol). Captopril also was most effective at changing blood pressure in WKY, while propranolol and hydralazine had similar blood pressure-lowering effects. The efficacy of drugs in preventing the development of smooth muscle cell polyploidism and medial hypertrophy in SHR was the same as their efficacy in lowering blood pressure, although propranolol had no effect on medial smooth muscle hypertrophy despite lowering blood pressure by 26 mm Hg. Regression analyses showed a high degree of correlation between blood pressure and the frequency of polyploid smooth muscle cells and medial smooth muscle content. These results are consistent with the hypothesis that aortic medial hypertrophy may be, in part, a response to increased blood pressure or wall stress. However, analysis of covariance and two-stage multiple regression analyses indicated that captopril had an effect over and above that predicted by its blood pressure-lowering effect. Furthermore, propranolol lowered blood pressure but did not affect medial hypertrophy. These results suggest that smooth muscle hypertrophy is not simply a response to increased blood pressure, but that other factors, such as angiotensin II, may be important in modulating aortic medial hypertrophy in SHR.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546119     DOI: 10.1161/01.hyp.9.2.178

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 2.  Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor.

Authors:  Mayank Chaudhary; Shashi Chaudhary
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 3.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 4.  Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II).

Authors:  J P Herrman; W R Hermans; J Vos; P W Serruys
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 5.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

6.  Isolation and characterization of clonal vascular smooth muscle cell lines from spontaneously hypertensive and normotensive rat aortas.

Authors:  K L Hall; J W Harding; H L Hosick
Journal:  In Vitro Cell Dev Biol       Date:  1991-10

7.  Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3.

Authors:  A Phillip Owens; Venkateswaran Subramanian; Jessica J Moorleghen; Zhenheng Guo; Coleen A McNamara; Lisa A Cassis; Alan Daugherty
Journal:  Circ Res       Date:  2009-12-17       Impact factor: 17.367

8.  Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin.

Authors:  H Weber; D S Taylor; C J Molloy
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift.

Authors:  Sasa Vukelic; Kathy K Griendling
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

10.  Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

Authors:  R Morishita; G H Gibbons; K E Ellison; W Lee; L Zhang; H Yu; Y Kaneda; T Ogihara; V J Dzau
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.